Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Assets: 2016-2025

Historic Other Non-Current Assets for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $40.5 million.

  • Akebia Therapeutics' Other Non-Current Assets rose 49.12% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 49.12%. This contributed to the annual value of $37.4 million for FY2024, which is 200.87% up from last year.
  • Per Akebia Therapeutics' latest filing, its Other Non-Current Assets stood at $40.5 million for Q3 2025, which was down 8.44% from $44.2 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Other Non-Current Assets registered a high of $69.6 million during Q3 2021, and its lowest value of $3.3 million during Q2 2023.
  • Its 3-year average for Other Non-Current Assets is $22.0 million, with a median of $17.8 million in 2024.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first crashed by 90.42% in 2023, then soared by 602.59% in 2024.
  • Akebia Therapeutics' Other Non-Current Assets (Quarterly) stood at $50.4 million in 2021, then crashed by 89.35% to $5.4 million in 2022, then skyrocketed by 131.25% to $12.4 million in 2023, then skyrocketed by 200.87% to $37.4 million in 2024, then surged by 49.12% to $40.5 million in 2025.
  • Its Other Non-Current Assets was $40.5 million in Q3 2025, compared to $44.2 million in Q2 2025 and $38.3 million in Q1 2025.